8-K: BIO-key International Issues New Warrants

BIO-key International has entered into a warrant exercise agreement, reducing the exercise price on existing warrants and issuing new warrants, contingent on shareholder approval.

Summary

• BIO-key International, Inc. (the Company) entered into a Warrant Exercise Agreement with an existing institutional investor on August 10, 2026.
• The agreement involves the exercise of existing warrants originally issued on October 28, 2025, for 618,334 shares of common stock.
• The exercise price for these existing warrants was reduced from $10.20 to $4.06 per share.
• In exchange for exercising the existing warrants, the investor received new, unregistered warrants to purchase up to 1,236,668 shares of common stock at an exercise price of $4.06 per share.
• These new warrants are subject to a beneficial ownership limitation of 4.99% and require shareholder approval from the Nasdaq Stock Market.
• The company received approximately $2.51 million in gross proceeds from the exercise of the existing warrants, before fees and expenses.
• The company is obligated to hold a shareholder meeting within 120 days to seek approval for the new warrants and to file a resale registration statement for the shares issuable upon exercise of the new warrants within 90 days.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development due to the issuance of new warrants at a reduced exercise price, which dilutes existing shareholders, despite the immediate capital infusion.

Positives

• The company received approximately $2.51 million in gross proceeds from the exercise of existing warrants, which can be used for working capital and general corporate purposes.
• The exercise price of existing warrants was reduced, potentially making them more attractive for exercise.
• The company is committed to seeking shareholder approval and filing a resale registration statement, indicating a path towards potential future liquidity for shares.

Negatives

• The issuance of new warrants at a reduced exercise price and a 200% coverage ratio (1,236,668 new warrants for 618,334 exercised shares) significantly dilutes existing shareholders.
• The exercise of the new warrants is contingent on shareholder approval, which may not be obtained.
• The company must hold shareholder meetings periodically until approval is obtained, incurring administrative costs.
• The company is obligated to file a resale registration statement, which involves legal and administrative costs.

Risks

• Failure to obtain shareholder approval for the new warrants could prevent their exercise and negate the intended capital raise.
• The company's reliance on warrant exercises and subsequent capital raises may indicate ongoing financial challenges.
• The beneficial ownership limitation of 4.99% on the new warrants could restrict the investor's ability to fully exercise them.
• The shares issuable upon exercise of the new warrants are unregistered and subject to resale restrictions until a registration statement is effective or an exemption is available.

Future Outlook

The company intends to use the net proceeds for working capital and general corporate purposes, potentially including the repayment of a portion of its outstanding secured note. The exercise of the new warrants is contingent on shareholder approval, and the company is committed to filing a resale registration statement for the underlying shares.

Management Comments

• The Company is pleased to offer to you the opportunity to receive new warrants to purchase shares of the Company's common stock in consideration for exercising for cash all of the Company's warrants to purchase an aggregate of 618,334 shares of Common Stock, issued to you on October 28, 2025 with an exercise price of $10.20 per share.
• The Company desires to reduce the Exercise Price of the Existing Warrants to $4.06 per share.
• The Company agrees to convene a stockholder meeting no later than 120 days following the date of the Warrant Exercise Agreement for the purpose of seeking the Stockholder Approval.
• The Company also agreed to file a resale registration statement covering the public resale of the shares of Common Stock issuable upon exercise of the New Warrants with the Securities and Exchange Commission (the SEC), and to use commercially reasonable efforts to have such Resale Registration Statement declared effective by the SEC within 90 days following the date of the Warrant Exercise Agreement.

Industry Context

StockSavvy.ai notes that this transaction is a common, albeit dilutive, method for companies, particularly those in growth or turnaround phases, to raise capital by restructuring existing debt or equity instruments. The reduction in exercise price and issuance of additional warrants can be seen as an inducement for the investor to provide immediate capital, but it comes at the cost of increased share dilution for existing shareholders.

Comparison to Industry Standards

• Issuing new warrants with a 200% coverage ratio (new warrants for exercised warrants) is a common practice in debt-for-equity or warrant restructuring transactions to incentivize investors.
• Reducing the exercise price from $10.20 to $4.06 is a significant concession, reflecting either a need for immediate capital or a belief that the current market price is substantially below the original warrant value.
• The requirement for shareholder approval for the issuance of new shares upon exercise of warrants is standard practice for companies listed on exchanges like Nasdaq, especially when the issuance could exceed certain thresholds.
• The commitment to file a resale registration statement within 90 days is a typical covenant in private placements involving unregistered securities, aiming to provide liquidity to the investor.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the issuance of new warrants, which could negatively impact earnings per share and stock value.
• Investors (Holder of Warrants): Benefit from a reduced exercise price on existing warrants and the opportunity to acquire new warrants, potentially leading to future gains if the stock price increases.
• Creditors: May see a reduction in outstanding secured note obligations if proceeds are used for repayment, which could improve the company's financial standing.

Next Steps

• Convene a stockholder meeting no later than 120 days following August 10, 2026, to seek shareholder approval for the new warrants.
• File a resale registration statement for the shares issuable upon exercise of the new warrants with the SEC, aiming for effectiveness within 90 days of August 10, 2026.
• Hold subsequent shareholder meetings every ninety (90) days if initial approval is not obtained.
• The company will maintain the listing or quotation of its Common Stock on the Nasdaq Capital Market and apply to list the new warrant shares on the same market.

Key Dates

Recommendation

The transaction provides immediate capital but at the cost of significant dilution, making the outlook uncertain. While the capital infusion is positive, the dilutive nature of the new warrants and the contingency on shareholder approval warrant a cautious 'hold' recommendation until further clarity on stockholder support and future performance is available.

Keywords

warrant exercise, common stock, capital raise, dilution, shareholder approval, registration statement, institutional investor, private placement